Single Rising Dose Study of MK-1708 in Healthy Participants

2023-506946-21-00 Protocol MK-1708-001 Human pharmacology (Phase I) - First administration to humans Ended

Start 24 Oct 2023 · End 2 Aug 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol MK-1708-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 24
Countries 1
Sites 1

Amyotrophic lateral sclerosis and Alzheimer’s disease

Key facts

Sponsor
Merck Sharp & Dohme LLC
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
24 Oct 2023 → 2 Aug 2024
Decision date (initial)
2023-10-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-506946-21-00
WHO UTN
U1111-1294-6795

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Amyotrophic lateral sclerosis and Alzheimer’s disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205
21.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Sharp & Dohme LLC

Sponsor organisation
Merck Sharp & Dohme LLC
Address
126 East Lincoln Avenue
City
Rahway
Postcode
07065-4607
Country
United States

Scientific contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Zoi Alexopoulou

Public contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Zoi Alexopoulou

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 24 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
Universitair Ziekenhuis Gent
DRUG, Corneel Heymanslaan 10, 9000, Gent

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2023-10-24 2024-08-01 2023-10-25 2024-06-27

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-04 Belgium Acceptable
2023-10-10
2023-10-13
2 SUBSTANTIAL MODIFICATION SM-1 2024-03-28 Belgium Acceptable
2024-05-07
2024-05-08